X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    NHS Acquires Potentially Lifesaving Breast Cancer Medication

    Transfusion of The First Patients Lab-Grown Blood Cells

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Report Indicates UK £62bn Behind In Global R&D Investment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    NHS Acquires Potentially Lifesaving Breast Cancer Medication

    Transfusion of The First Patients Lab-Grown Blood Cells

    Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

    $2 Million Gene Therapy Might Become The Standard In The US

    $2 Million Gene Therapy Might Become The Standard In The US

    Cancer Medicine Prices Jump 53% In Five Years In The U.S

    Food And Drug Administration User Fee Has Been Reauthorized

    Cancer Clinical Trials Get A Brand New Platform In Melbourne

    Report Indicates UK £62bn Behind In Global R&D Investment

    Report Indicates UK £62bn Behind In Global R&D Investment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Europe

Selincro (nalmefene) – Treatment for Alcohol Dependence

Yuvraj_pawp by Yuvraj_pawp
8th August 2014
in Europe, Projects

Selincro (nalmefene) is an injected drug for the treatment of alcohol dependence. The drug was originally developed by Key Pharmaceuticals in the 1980s and 90s. In 1998 Biotie Therapies obtained the rights to the compound, and started clinical trials in 1999.

In 2006, Lundbeck purchased the global manufacturing and development rights to Selincro from Biotie for a sum of €12m and an upfront payment of €84m as a sales milestone.

Lundbeck initiated Phase III (ESSENSE 2) clinical trials on the drug in March 2009. It submitted the European Marketing Authorisation Application (MAA) in December 2011.

The European Medicines Agency (EMA) accepted Selincro for review. Lundbeck has received a positive opinion from the committee for medicinal products for human use (CHMP).

Alcohol dependence

 

Addiction to alcohol or alcohol dependence is a disease usually known as alcoholism. The afflicted person develops a strong desire for alcohol and is unable to limit their drinking amounts.

“In 2006, Lundbeck purchased the global manufacturing rights to nalmefene.”

Selincro, an opioid receptor antagonist

 

Nalmefene contains an opioid receptor antagonist, which inhibits the reward pathway in the brain that reinforces the strong desire for alcohol and other substances in addicts.

The drug contains a 6-methylene analogue of naltrexone in injectable form. It works by blocking opiate receptors that prevent toxic effects of narcotic analgesics.

Clinical trials

 

Lundbeck conducted a set of Phase III clinical trials called ESSENSE1 from December 2008 to November 2010 across Austria, Sweden, Germany and Finland. The study enrolled 598 alcohol dependants as per DSM- IV-TR standards.

The purpose was to evaluate the efficacy and safety of Nalmefene against a placebo in a 24 week timeframe. The primary outcome measure was to find the change in the monthly number of heavy drinking days from the baseline and also the change in total alcohol consumption from the baseline. The secondary outcome measures included finding the liver function, pharmacoeconomic outcomes, tolerability and safety of the drug and the treatment discontinuation effects.

A second set of Phase III trials named ESSENSE 2 were initiated in March 2009. It enrolled 718 participants and was completed in June 2011. The purpose was to evaluate the efficacy and safety of nalmefene in treating alcohol dependency against a placebo. The primary outcome was to measure the change in the number of heavy drinking days from the baseline. The change in total alcohol consumption from the baseline in a 24-week time frame was measured. The secondary outcome measures included pharmacoeconomic outcomes and safety and tolerability of the drug in treating alcohol dependence.

The results of the study demonstrated that nalmefene has a significant potential to help individuals with alcohol dependence in reducing their alcohol consumption. The people administered with nalmefene showed reduction in heavy drinking days. The study also found that nalmefene was safe and well-tolerated.

The company also conducted Phase III clinical trials on the drug from March 2009 to November 2010 across 61 centres worldwide. Known as SENSE, the study enrolled 665 alcohol dependants who were diagnosed as per DSM (Diagnostic and Statistical Manual of Mental Disorders) -IV-TR.

“Nalmefene contains an opioid receptor antagonist.”

The purpose of the study was to establish the tolerability and long-term safety of nalmefene against a placebo. The primary outcome measure was to check the safety of the drug by measuring the adverse events, vital signs, body mass index, weight, clinical laboratory tests outcomes, physical examinations and electrocardiograms within a time frame of 52 weeks.

The secondary outcome measures included finding pharmacoeconomic outcomes, liver function, and reduction of alcohol consumption and dependence symptoms in 52 weeks.

Marketing commentary

 

One in 10 deaths in the western world is alcohol-related. Europe alone has about 23m alcohol dependents. Treating alcohol dependence is a large unmet medical need. It is the most under diagnosed disease, with just about 13% of alcohol dependants receiving treatment. Currently there are only a few medicines that have received the marketing approval for treating alcoholics.

 

Tags: Europe
Previous Post

Wilate, von Willebrand Factor/Coagulation Factor Concentrate

Next Post

Mirapex (Pramipexole) - Treatment for Parkinson's Disease

Related Posts

Dr Reddy's Lab gets DCGI nod for Sputnik Phase 2 & 3 trials
Europe

RDIF and Minapharm Agree to Produce over 40 Million Doses of the Sputnik V Vaccine in Egypt

26th April 2021
Sputnik V: World's First COVID-19 Vaccine Now Available to Public in Russia
Europe

Sputnik V: World’s First COVID-19 Vaccine Now Available to Public in Russia

26th September 2020
AstraZeneca agrees to supply Europe with 400 million doses of COVID-19 vaccine
Europe

Valneva Announces Major COVID-19 Vaccine Partnership with U.K. Government

21st September 2020
Europe

Pharmintech 2019: Big increase in International Participation Expected

18th November 2018
Europe

Novo Nordisk acquires Ziylo Ltd to accelerate its development of glucose responsive insulins

17th August 2018
Europe

Chemspec Europe 2018 in Cologne closes with a record in visitor numbers

6th July 2018
Next Post

Mirapex (Pramipexole) - Treatment for Parkinson's Disease

Latest News

FDA Approvals

NHS Acquires Potentially Lifesaving Breast Cancer Medication

9th November 2022
Clinical Trials

Transfusion of The First Patients Lab-Grown Blood Cells

9th November 2022
Clinical Trials

Bispecific Cancer Drugs, Gene Therapy Advances At Next ASH

8th November 2022
India Seeks Better Pharma Market Access In The UK: Official
Facilities & Operation

India Seeks Better Pharma Market Access In The UK: Official

8th November 2022
First Virtual Drug Study Tests 2 Likely Alzheimer Therapies
Clinical Trials

First Virtual Drug Study Tests 2 Likely Alzheimer Therapies

7th November 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In